Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Black Diamond Therapeutics stock | $7.89

Learn how to easily invest in Black Diamond Therapeutics stock.

Black Diamond Therapeutics Inc is a biotechnology business based in the US. Black Diamond Therapeutics shares (BDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Black Diamond Therapeutics employs 69 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Black Diamond Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BDTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Black Diamond Therapeutics stock price (NASDAQ: BDTX)

Use our graph to track the performance of BDTX stocks over time.

Black Diamond Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$7.89
52-week range$7.55 - $37.76
50-day moving average $8.85
200-day moving average $13.86
Wall St. target price$31.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.92

Buy Black Diamond Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Black Diamond Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Black Diamond Therapeutics price performance over time

Historical closes compared with the close of $7.89 from 2021-10-26

1 week (2021-10-16) N/A
1 month (2021-09-27) -19.16%
3 months (2021-07-27) -12.91%
6 months (2021-04-27) -71.99%
1 year (2020-10-27) -75.89%
2 years (2019-10-23) N/A
3 years (2018-10-23) N/A
5 years (2016-10-23) N/A

Black Diamond Therapeutics financials

Gross profit TTM $0
Return on assets TTM -21%
Return on equity TTM -35.41%
Profit margin 0%
Book value $6.93
Market capitalisation $293.3 million

TTM: trailing 12 months

Shorting Black Diamond Therapeutics shares

There are currently 3.9 million Black Diamond Therapeutics shares held short by investors – that's known as Black Diamond Therapeutics's "short interest". This figure is 7.7% down from 4.2 million last month.

There are a few different ways that this level of interest in shorting Black Diamond Therapeutics shares can be evaluated.

Black Diamond Therapeutics's "short interest ratio" (SIR)

Black Diamond Therapeutics's "short interest ratio" (SIR) is the quantity of Black Diamond Therapeutics shares currently shorted divided by the average quantity of Black Diamond Therapeutics shares traded daily (recently around 261441.23572868). Black Diamond Therapeutics's SIR currently stands at 14.89. In other words for every 100,000 Black Diamond Therapeutics shares traded daily on the market, roughly 14890 shares are currently held short.

However Black Diamond Therapeutics's short interest can also be evaluated against the total number of Black Diamond Therapeutics shares, or, against the total number of tradable Black Diamond Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Black Diamond Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Black Diamond Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1721% of the tradable shares (for every 100,000 tradable Black Diamond Therapeutics shares, roughly 172 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Black Diamond Therapeutics.

Find out more about how you can short Black Diamond Therapeutics stock.

Black Diamond Therapeutics share dividends

We're not expecting Black Diamond Therapeutics to pay a dividend over the next 12 months.

Black Diamond Therapeutics overview

Black Diamond Therapeutics, Inc. , a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics in the news

There are no recent company news

Frequently asked questions

What percentage of Black Diamond Therapeutics is owned by insiders or institutions?
Currently 3.638% of Black Diamond Therapeutics shares are held by insiders and 90.209% by institutions.
How many people work for Black Diamond Therapeutics?
Latest data suggests 69 work at Black Diamond Therapeutics.
When does the fiscal year end for Black Diamond Therapeutics?
Black Diamond Therapeutics's fiscal year ends in December.
Where is Black Diamond Therapeutics based?
Black Diamond Therapeutics's address is: One Main Street, Cambridge, MA, United States, 02142
What is Black Diamond Therapeutics's ISIN number?
Black Diamond Therapeutics's international securities identification number is: US09203E1055
What is Black Diamond Therapeutics's CUSIP number?
Black Diamond Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09203E105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site